XML 19 R10.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenue | 3 Months Ended
--- | ---
Mar. 31, 2023
Revenue from Contract with Customer [Abstract] |
Revenue | Revenue The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Net product revenue | $ | 6,238.2 |  |  | $ | 7,132.9 |  |  |  |  |
Collaboration and other revenue(1) | 721.8 |  |  | 677.1 |  |  |  |  |
Revenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  |  |  |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March 31, 2023 and 2022, respectively. We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance® and Trajenta® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers. Adjustments to Revenue Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three months ended March 31, 2023 and 2022. Contract Liabilities Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. The following table summarizes contract liability balances:
| March 31, 2023 |  | December 31, 2022
Contract liabilities | $ | 220.3 |  |  | $ | 219.2 |
During the three months ended March 31, 2023 and 2022, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year. Disaggregation of Revenue The following table summarizes revenue by product for the three months ended March 31, 2023 and 2022:
| Three Months Ended March 31,
| 2023 |  | 2022
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Revenue—to unaffiliated customers: |  |  |  |  |  |  |
Diabetes: |  |  |  |  |  |  |
Trulicity® | $ | 1,547.4 |  | $ | 429.7 |  | $ | 1,977.1 |  |  | $ | 1,313.9 |  | $ | 427.4 |  | $ | 1,741.3 |
Jardiance(1) | 329.4 |  | 248.1 |  | 577.5 |  |  | 229.8 |  | 189.7 |  | 419.4 |
Mounjaro® | 536.4 |  | 32.0 |  | 568.5 |  |  | — |  | — |  | — |
Humalog® (2) | 271.6 |  | 189.3 |  | 460.9 |  |  | 368.9 |  | 249.3 |  | 618.2 |
Humulin® | 198.8 |  | 53.2 |  | 252.0 |  |  | 190.4 |  | 82.8 |  | 273.2 |
Basaglar® | 135.4 |  | 73.9 |  | 209.3 |  |  | 119.3 |  | 72.2 |  | 191.5 |
Other diabetes | 56.0 |  | 89.2 |  | 145.1 |  |  | 54.3 |  | 90.2 |  | 144.6 |
Total diabetes | 3,075.0 |  | 1,115.4 |  | 4,190.4 |  |  | 2,276.6 |  | 1,111.6 |  | 3,388.2 |
Oncology: |  |  |  |  |  |  |
Verzenio® | 461.1 |  | 289.8 |  | 750.9 |  |  | 301.5 |  | 167.9 |  | 469.4 |
Cyramza® | 100.6 |  | 136.1 |  | 236.8 |  |  | 79.2 |  | 151.1 |  | 230.3 |
Erbitux® | 118.8 |  | 11.1 |  | 129.9 |  |  | 109.7 |  | 13.0 |  | 122.7 |
Alimta® | 20.1 |  | 38.1 |  | 58.2 |  |  | 254.3 |  | 89.7 |  | 343.9 |
Other oncology | 52.8 |  | 127.5 |  | 180.2 |  |  | 39.0 |  | 147.5 |  | 186.7 |
Total oncology | 753.4 |  | 602.6 |  | 1,356.0 |  |  | 783.7 |  | 569.2 |  | 1,353.0 |
Immunology: |  |  |  |  |  |  |
Taltz® | 312.2 |  | 214.8 |  | 527.0 |  |  | 307.2 |  | 180.8 |  | 488.1 |
Olumiant® (3) | 42.3 |  | 186.5 |  | 228.9 |  |  | 71.3 |  | 184.3 |  | 255.6 |
Other immunology | — |  | 22.0 |  | 22.0 |  |  | — |  | 4.5 |  | 4.5 |
Total immunology | 354.5 |  | 423.3 |  | 777.8 |  |  | 378.5 |  | 369.6 |  | 748.1 |
Neuroscience: |  |  |  |  |  |  |
Emgality® | 108.7 |  | 45.6 |  | 154.3 |  |  | 108.3 |  | 41.0 |  | 149.3 |
Other neuroscience | 35.8 |  | 170.4 |  | 206.2 |  |  | 45.1 |  | 203.4 |  | 248.4 |
Total neuroscience | 144.5 |  | 216.0 |  | 360.5 |  |  | 153.4 |  | 244.4 |  | 397.7 |
Other: |  |  |  |  |  |  |
Forteo® | 70.7 |  | 51.7 |  | 122.3 |  |  | 70.2 |  | 67.3 |  | 137.4 |
Cialis® | 7.6 |  | 92.7 |  | 100.3 |  |  | 6.9 |  | 210.8 |  | 217.7 |
COVID-19 antibodies(4) | — |  | — |  | — |  |  | 1,455.2 |  | 14.7 |  | 1,469.8 |
Other | 30.5 |  | 22.2 |  | 52.8 |  |  | 50.1 |  | 47.8 |  | 98.1 |
Total other | 108.7 |  | 166.6 |  | 275.3 |  |  | 1,582.4 |  | 340.6 |  | 1,923.0 |
Revenue | $ | 4,436.2 |  | $ | 2,523.9 |  | $ | 6,960.0 |  |  | $ | 5,174.6 |  | $ | 2,635.4 |  | $ | 7,810.0 |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (2) Humalog revenue includes insulin lispro. (3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area:
| Three Months Ended March 31, |  |
| 2023 |  | 2022 |  |  |  |
Revenue—to unaffiliated customers(1): |  |  |  |  |  |  |
U.S. | $ | 4,436.2 |  |  | $ | 5,174.6 |  |  |  |  |
Europe | 1,090.9 |  |  | 1,067.3 |  |  |  |  |
Japan | 387.2 |  |  | 410.2 |  |  |  |  |
China | 372.7 |  |  | 406.5 |  |  |  |  |
Other foreign countries | 673.1 |  |  | 751.5 |  |  |  |  |
Revenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  |  |  |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration